Poseida Therapeutics Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Kristin Yarema
Algemeen directeur
US$2.6m
Totale compensatie
| Percentage CEO-salaris | 14.7% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 3.5yrs |
Recente managementupdates
Recent updates
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Oct 19
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Sep 30Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$3m | US$381k | -US$123m |
Compensatie versus markt: De totale vergoeding ($USD 2.58M ) Kristin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.47M ).
Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Kristin te vergelijken met de prestaties van het bedrijf.
CEO
Kristin Yarema (53 yo)
less than a year
Tenure
US$2,581,106
Compensatie
Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.8yrs | US$3.82m | 0.15% $ 394.3k | |
| President | less than a year | US$2.58m | geen gegevens | |
| Chief Financial Officer | 4.3yrs | geen gegevens | 0.073% $ 192.3k | |
| Chief Operations Officer | 2.8yrs | geen gegevens | geen gegevens | |
| Chief People & Administration Officer | 5.8yrs | geen gegevens | geen gegevens | |
| Senior VP of Investor Relations & Corporate Communications | less than a year | geen gegevens | geen gegevens | |
| General Counsel | 4.3yrs | US$978.34k | 0.040% $ 106.6k | |
| Chief Scientific Officer of Cell Therapy | 4.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs | 3.1yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Patent Counsel | 2.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Business Development | 2.8yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | less than a year | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PSTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.8yrs | US$3.82m | 0.15% $ 394.3k | |
| President | less than a year | US$2.58m | geen gegevens | |
| Lead Independent Director | 6.3yrs | US$175.11k | 0.040% $ 106.5k | |
| Chairman of Cell Therapy Scientific Advisory Board | 3.7yrs | geen gegevens | geen gegevens | |
| Chairman of Gene Therapy Scientific Advisory Board | 2.3yrs | geen gegevens | geen gegevens | |
| Independent Director | 5.8yrs | US$149.11k | 0.051% $ 133.6k | |
| Independent Director | 3.3yrs | US$155.28k | 0.040% $ 106.5k | |
| Independent Director | 2.5yrs | US$150.28k | 0.047% $ 124.2k | |
| Independent Director | 3.9yrs | US$140.11k | 0.040% $ 106.5k | |
| Member of Scientific Advisory Board | 3.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 3.5yrs | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PSTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).